|
Biological Activity:
An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer.
Note: The hydrochloride salt of PD 0332991 is water soluble, ideal for in vivo experiments.
References:
RL Sutherland and EA Musgrove. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009, 11(6), 112-113.
RS Finn et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11(5), R77. [online]
DW Fry et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438.
Chemical Name: 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride
| 
